Insilico collaborates with Teva on AI system for target discovery

 

Insilico enters into a collaboration with Teva to apply novel generative artificial intelligence for the discovery of potential therapeutic targets

Tuesday, June 22, 2021 - Insilico Medicine is pleased to announce that it has entered into a collaboration with Teva Branded Pharmaceutical Products R&D, Inc. to utilize Insilico's generative machine learning technology and proprietary PandaOmics Drug Discovery Platform, which aims at identifying novel therapeutic targets implicated in a variety of diseases.

"Teva is a global leader in generics and specialty medicines, and we are happy to be contributing to its research and development efforts, especially in the field of novel target discovery," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.

PandaOmics is a comprehensive AI-powered platform for novel target discovery integrating over 60 different engines and approaches to target discovery. It provides biologically interpretable insights coupled with business intelligence with multiple experimentally validated case studies.

###

About Insilico Medicine:

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/.